Richard Mortimer - The Competitive Landscape for Biosimilars

August 2018

While intellectual property and antitrust litigation involving pharmaceuticals has long been widespread in the US, the recent emergence of biosimilar drugs has raised a number of questions around how this litigation will evolve.